A multicountry, single‑arm pivotal trial of the SAPIEN M3 transseptal transcatheter mitral valve replacement (TMVR) in patients deemed unsuitable for surgery or TEER demonstrated a 1‑year composite rate of death or heart‑failure rehospitalisation of 25.2%, significantly below the prespecified 45% performance goal, with few intraprocedural complications.